Clinical Trial

PRELUDE-1 (Prospective Evaluation of Radiotherapy-induced Biologic Effects in Colorectal Cancer Oligometastatic Patients with LUng-limited Disease: Evolution of Cancer Genetics and Regulatory Immune Cells)

Study acronym: PRELUDE-1
Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated November 7, 2024 (before its estimated January 2025 completion). Its status may not reflect the trial's current state.
Summary
PRELUDE-1 study is a pilot intervention trial that aims to describe the immunologic and genetic evolutions induced by stereotactic body radiationtherapy (SBRT) treatment in oligometastatic Colorectal Cancer (omCRC) patients with two-three nodules lung-limited disease.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2021-04-16; most recent amendment 2024-11-05.
Status change: Not Yet Recruiting → Recruiting 2022-04-06
Trial Details
NCT Number NCT04854213
Lead Sponsor National Cancer Institute, Naples
Conditions Colorectal Cancer Metastatic
Enrollment 25 participants
Start Date 2021-10-06
Primary Completion 2025-01 (estimated)
Study Completion 2025-03 (estimated)
Updated on ClinicalTrials.gov 2024-11-07